How to kill h pylori at home
Reading File
Finding Sources
Searching PubMed
"Helicobacter pylori" AND eradication AND treatment
Searching the Web
H pylori home treatment natural remedies evidence 2025
Finding Sources
Reading File
Reading File
I now have enough information from Harrison's (2025 edition), Sleisenger & Fordtran's, and web sources to give a thorough, evidence-based answer. Here it is:
H. pylori: What You Can (and Can't) Do at Home
The core reality: antibiotics are required for eradication
H. pylori does not go away on its own. As Harrison's Principles of Internal Medicine (2025) states directly: "Helicobacter pylori colonizes the stomach essentially for life unless eradicated by antibiotic treatment." There is no home remedy that has been shown in clinical trials to fully eradicate the infection.
The standard treatment (triple therapy) prescribed by doctors includes:
- Two antibiotics (typically clarithromycin + amoxicillin, or metronidazole + tetracycline)
- A proton pump inhibitor (PPI) like omeprazole
- Sometimes bismuth subsalicylate (Pepto-Bismol) as a 4th agent
You need to see a doctor to get this treatment. Attempting to self-treat with just natural remedies risks the infection persisting and progressing to peptic ulcers, or - in the long term - gastric cancer. - Harrison's Principles of Internal Medicine 22E, p. 1342
What home measures genuinely help (as adjuncts, not cures)
These are supported by research but should supplement, not replace, medical treatment:
1. Probiotics
The best-supported adjunct. A 2024 umbrella review of 534 RCTs found that multi-strain probiotics (especially Lactobacillus and Bifidobacterium strains) significantly improve eradication rates and reduce antibiotic side effects (nausea, diarrhea) when taken alongside standard therapy. Take them 2+ hours apart from antibiotics.
2. Broccoli sprouts (sulforaphane)
Contains sulforaphane, which has shown anti-H. pylori activity in human studies. Eating them regularly may reduce bacterial load.
3. Manuka honey / raw honey
Has direct antibacterial effects against H. pylori in lab and some clinical studies. Will not eradicate the bacteria alone, but may inhibit growth and support gastric healing.
4. Green tea
Catechins (antioxidants in green tea) inhibit H. pylori growth. Both animal and human studies support this. Drink 2-3 cups daily.
5. Extra virgin olive oil
Polyphenols (hydroxytyrosol, oleuropein) show antimicrobial activity against H. pylori and remain stable in stomach acid. Use it regularly in food.
6. Garlic
Allicin in garlic has shown anti-H. pylori activity in lab studies. Add raw garlic to meals regularly.
7. Cranberry
Proanthocyanidins in cranberry may prevent H. pylori from adhering to stomach tissue - useful for preventing reinfection. Drink unsweetened cranberry juice or take extract.
8. Mastic gum
A resin from the mastic tree - shows some inhibitory effect on H. pylori in studies. Available as a supplement.
9. Turmeric / curcumin
Shows anti-H. pylori and anti-inflammatory activity in gastric mucosa. Add to food or take as supplement.
Diet and lifestyle changes that reduce symptoms and support healing
| Do more of | Avoid |
|---|---|
| Small, frequent cooked meals | Alcohol (damages gastric lining) |
| Probiotic-rich foods (yogurt, kefir) | Smoking (increases treatment failure, per Sleisenger & Fordtran's) |
| Fruits, vegetables, fiber | Processed/fried foods |
| Ginger (anti-inflammatory, anti-nausea) | Spicy foods if they trigger pain |
| Adequate hydration | NSAIDs (ibuprofen, aspirin) - worsen ulcers |
Symptoms that mean you need a doctor NOW
- Black, tarry, or bloody stools (sign of bleeding ulcer)
- Vomiting blood or coffee-ground material
- Severe, persistent stomach pain
- Unintentional weight loss
- Difficulty swallowing
These are warning signs of complications (bleeding ulcer, perforation, malignancy) that require urgent medical care.
Bottom line
Natural remedies like probiotics, green tea, broccoli sprouts, and manuka honey can help reduce symptoms and support treatment - but none of them eradicate H. pylori on their own. The only proven cure is a course of prescription antibiotics from a doctor. If you have confirmed H. pylori (via breath test, stool antigen test, or endoscopy biopsy), please seek treatment. It is a highly treatable condition, and eradicating it greatly reduces your lifetime risk of peptic ulcers and gastric cancer. - Harrison's Principles of Internal Medicine 22E, Sleisenger & Fordtran's Gastroenterology
H pylori stool antigen test
Finding Sources
Searching the Web
H pylori stool antigen test accuracy sensitivity specificity guidelines 2025
Reading File
Reading File
Excellent data from Harrison's 22E (2025) and Yamada's Gastroenterology. Here is the complete breakdown:
H. pylori Stool Antigen Test (HpSA)
What it is
The H. pylori stool antigen test (HpSA) detects H. pylori bacterial antigens directly in feces using an enzyme immunoassay (EIA). The standard format is a sandwich ELISA: polyclonal or monoclonal anti-H. pylori antibodies are bound to microtiter wells, the stool sample is added, antigens are "captured," and a color change indicates a positive result. Rapid immunochromatographic card versions are also available and give results in ~30 minutes. - Yamada's Textbook of Gastroenterology, 7th ed.
Two uses
| Use | Timing |
|---|---|
| Initial diagnosis of active infection | Anytime (with preparation - see below) |
| Test of cure - confirm eradication after treatment | ≥4 weeks after completing antibiotics |
Accuracy
| Parameter | Value |
|---|---|
| Sensitivity | 91-96% (laboratory EIA); up to 100% with newer monoclonal tests |
| Specificity | 94-96% |
| PPV | ~95% |
| NPV | ~92% |
| Overall accuracy | ~94% |
Monoclonal antibody-based tests are more accurate than older polyclonal tests. The urea breath test (UBT) is slightly superior for specificity, but the stool antigen test is less expensive and more convenient. - Yamada's Textbook of Gastroenterology, 7th ed.; Harrison's Principles of Internal Medicine 22E
Key advantages over other tests
- Non-invasive - no endoscopy needed
- Detects active infection - unlike serology (IgG), which stays positive long after eradication
- FDA-approved for both initial diagnosis and post-treatment monitoring in adults
- Safe and accurate in children (pediatric use validated)
- Cost-effective
- PPI use does NOT affect stool antigen accuracy - unlike the urea breath test or biopsy-based techniques, which can give false negatives if the patient is taking PPIs
Important preparation rules (to avoid false negatives)
This is where most errors happen:
| Medication | Stop before testing |
|---|---|
| Antibiotics or bismuth | ≥4 weeks before the test |
| Proton pump inhibitors (PPIs) (omeprazole, pantoprazole, etc.) | ≥2 weeks before the test |
| H2 blockers (ranitidine, famotidine) | Generally no washout needed |
PPIs reduce bacterial load and can cause false negatives in breath testing, but the stool antigen test is more resistant to PPI effect than the urea breath test. Still, stopping PPIs for 2 weeks before testing is recommended for optimal accuracy. - Harrison's Principles of Internal Medicine 22E, p. 1343
Post-treatment (test of cure)
- Perform no earlier than 4 weeks after finishing antibiotics
- Testing too early gives false negatives because bacterial numbers are suppressed but not yet fully eliminated - regrowth can still occur
- After successful eradication, stool antigen levels drop rapidly and become undetectable within 5 days of completing treatment in most patients
- Serologic tests (blood IgG) are not suitable for confirming cure - antibody titers fall too slowly (>14 weeks) to be clinically useful - Harrison's Principles of Internal Medicine 22E
How it compares to other H. pylori tests
| Test | Detects active infection | Post-treatment use | Invasive | Cost | Notes |
|---|---|---|---|---|---|
| Stool antigen (HpSA) | Yes | Yes (≥4 wks) | No | Low | Best non-invasive option |
| Urea breath test (UBT) | Yes | Yes (≥4 wks) | No | Moderate | Slightly better specificity; affected by PPIs |
| Serology (IgG) | No (past exposure) | No | No | Low | Cannot confirm eradication; not recommended as sole test |
| Rapid urease test (CLO) | Yes | Yes | Yes (endoscopy) | Moderate | Requires biopsy |
| Histology | Yes | Rarely needed | Yes (endoscopy) | High | Gold standard, also shows mucosal damage |
| Culture | Yes | Rarely | Yes (endoscopy) | High | Used for antibiotic resistance testing |
Maastricht VI / current guidelines say:
- For patients not needing endoscopy: use urea breath test or stool antigen test for both initial diagnosis and post-treatment confirmation
- Stool antigen is recommended over serology for diagnosis
- Do not use serology to confirm eradication
- Test of cure with stool antigen or UBT is recommended for all patients after treatment - Maastricht VI/Florence Consensus
Practical summary
The stool antigen test is the most practical non-invasive test for diagnosing and confirming eradication of H. pylori. Stop PPIs for 2 weeks and antibiotics/bismuth for 4 weeks before testing. For test of cure, wait at least 4 weeks after finishing treatment. A positive test = active infection; a negative test after treatment = successful eradication.
H. pylori treatment regimens and eradication rates
Finding Sources
Finding Sources
Searching PubMed
"Helicobacter pylori" AND eradication AND "first-line" AND therapy
Searching the Web
H pylori treatment regimens eradication rates guidelines 2024 2025 ACG Maastricht
Reading File
Reading File
Reading File
Reading File
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC12708901
I now have comprehensive data from Harrison's 22E, Goldman-Cecil, Yamada's, Washington Manual, and the 2024 ACG guideline + 2025 PMC review. Here is the complete answer:
H. pylori Treatment Regimens and Eradication Rates
The key principle driving regimen choice: antibiotic resistance
The single most important factor in selecting a regimen is local clarithromycin resistance:
- Clarithromycin resistance: 10-50% in many regions (was rare; rose due to macrolide use for respiratory infections)
- Metronidazole resistance: 20-80% worldwide
- Levofloxacin resistance: 10-50% in many regions (rising fast)
- Amoxicillin and tetracycline resistance: rare, not clinically significant in most settings
When clarithromycin resistance is >15-20%, standard clarithromycin triple therapy eradication rates drop to as low as 30% and should not be used empirically.
First-Line Regimens
1. Bismuth Quadruple Therapy (BQT) - Preferred first-line globally (ACG 2024)
| Component | Dose |
|---|---|
| PPI | Standard dose twice daily |
| Bismuth subsalicylate | 525 mg four times daily |
| Tetracycline | 500 mg four times daily |
| Metronidazole | 250-500 mg four times daily |
| Duration | 14 days |
- Eradication rate: 85-90%
- Works regardless of clarithromycin resistance (no clarithromycin involved)
- Preferred when clarithromycin resistance is unknown or high
- ACG 2024 recommends BQT as first-line for most patients in the US
- Packaged as Pylera (bismuth + metronidazole + tetracycline capsules)
- Side effects: dark stools, black tongue (bismuth), nausea, dysgeusia
2. Clarithromycin Triple Therapy (Standard Triple Therapy / STT)
| Component | Dose |
|---|---|
| PPI | Standard dose twice daily |
| Clarithromycin | 500 mg twice daily |
| Amoxicillin | 1 g twice daily (or metronidazole 500 mg bid if penicillin allergy) |
| Duration | 14 days (not 7; shorter duration is inferior) |
- Eradication rate: 70-85% (where clarithromycin resistance <15%)
- Drops to ~30% with clarithromycin-resistant strains
- Available as Prevpac (lansoprazole + clarithromycin + amoxicillin) but 7-day Prevpac is suboptimal
- ACG 2024: acceptable first-line only where clarithromycin resistance is reliably <15%
- Most guidelines now discourage this as empiric first-line therapy in most parts of the world
3. Concomitant Therapy (Non-Bismuth Quadruple)
| Component | Dose |
|---|---|
| PPI | Standard dose twice daily |
| Clarithromycin | 500 mg twice daily |
| Amoxicillin | 1 g twice daily |
| Metronidazole | 500 mg twice daily |
| Duration | 14 days |
- Eradication rate: ~85-90%
- All four drugs given simultaneously throughout the course
- Most effective of the non-bismuth quadruple regimens, especially with high-dose PPI (omeprazole 40 mg bid equivalent)
- Recommended as an alternative when bismuth is unavailable
- Goldman-Cecil Medicine: "Concomitant therapy, which gives these same drugs all together for 14 days, is the most effective [non-bismuth quadruple]"
4. Sequential Therapy
| Phase | Duration | Components |
|---|---|---|
| Phase 1 | 5-7 days | PPI + amoxicillin 1 g bid |
| Phase 2 | 5-7 days | PPI + clarithromycin 500 mg bid + metronidazole 500 mg bid |
| Total | 10-14 days |
- Eradication rate: ~85% (10-day regimen = comparable to 14-day triple therapy)
- Rationale: amoxicillin first reduces bacterial load and disrupts efflux pumps, improving clarithromycin efficacy
- Less used now; concomitant therapy generally preferred
5. Vonoprazan-Based Therapy (newest, FDA-approved 2022)
Vonoprazan is a potassium-competitive acid blocker (P-CAB) that suppresses gastric acid more potently and consistently than PPIs, improving antibiotic stability in the stomach.
a) Vonoprazan Dual Therapy
| Component | Dose | Duration |
|---|---|---|
| Vonoprazan | 20 mg twice daily | 14 days |
| Amoxicillin | 1 g three times daily | 14 days |
- Eradication rate: >90% (PP analysis), especially in Asian populations
- VA-dual therapy shown non-inferior to vonoprazan-amoxicillin-clarithromycin (VAC) triple therapy in recent RCTs
- Fewer adverse effects than BQT
- ITT eradication: ~77-84% (lower than PP due to non-completers)
b) Vonoprazan Triple Therapy (VAC)
| Component | Dose | Duration |
|---|---|---|
| Vonoprazan | 20 mg twice daily | 14 days |
| Amoxicillin | 1 g twice daily | 14 days |
| Clarithromycin | 500 mg twice daily | 14 days |
- Eradication rate: ~85-93%
- Superior to lansoprazole triple therapy in clarithromycin-resistant strains (70% vs. 32%)
- ACG 2024 recommends vonoprazan-based regimens as suitable first-line alternatives, especially where clarithromycin resistance is high
- ACG 2024 H. pylori Treatment Guideline
6. Rifabutin Triple Therapy (Talicia - FDA-approved)
| Component | Dose | Duration |
|---|---|---|
| Omeprazole | 40 mg three times daily | 14 days |
| Amoxicillin | 1 g three times daily | 14 days |
| Rifabutin | 50 mg three times daily | 14 days |
- Eradication rate: ~80-84%
- Available as pre-packaged Talicia capsules
- ACG 2024 lists rifabutin triple therapy as a suitable empiric first-line alternative for patients without penicillin allergy
- Key advantage: rifabutin resistance in H. pylori remains very low
- Side effect concern: myelosuppression (rare), uveitis with rifabutin at higher doses
Eradication Rates Summary Table
| Regimen | Duration | Eradication Rate | Notes |
|---|---|---|---|
| Bismuth quadruple (BQT) | 14 days | 85-90% | Preferred globally; ACG 2024 first-line |
| Concomitant therapy | 14 days | 85-90% | Best non-bismuth option |
| Vonoprazan + amoxicillin (dual) | 14 days | >90% (PP) | High in Asian populations |
| Vonoprazan + amoxicillin + clarithromycin | 14 days | 85-93% | Superior in clarithromycin-resistant cases |
| Clarithromycin triple therapy | 14 days | 70-85% | Only where clarithromycin resistance <15% |
| Clarithromycin triple (resistant strain) | 14 days | ~30% | Avoid empirically |
| Sequential therapy | 10-14 days | ~85% | Comparable to triple; less used now |
| Rifabutin triple (Talicia) | 14 days | ~80-84% | Low resistance rates; first-line alternative |
Second-Line (Salvage) Therapy
When first-line fails, avoid repeating antibiotics already used (especially clarithromycin or metronidazole if used initially).
| Regimen | Notes |
|---|---|
| BQT (if not used first-line) | 80% eradication in second-line setting |
| Levofloxacin triple therapy (PPI + levofloxacin 250 mg bid + amoxicillin 1 g bid, 14 days) | Second-line; rising resistance limits use |
| Fluoroquinolone sequential (PPI + amoxicillin x 5-7 days → PPI + levofloxacin + metronidazole x 5-7 days) | Alternative second-line |
| Rifabutin triple (Talicia) | Salvage for multiple prior failures |
| Bismuth + levofloxacin + amoxicillin + PPI | Salvage combination |
| Culture-guided susceptibility therapy | Best option after 2+ failures; 88% eradication vs. 78% empiric |
Special Populations
| Situation | Recommended approach |
|---|---|
| Penicillin allergy | BQT (no amoxicillin needed); or clarithromycin + metronidazole + PPI |
| Prior macrolide exposure | Avoid clarithromycin; use BQT or metronidazole + amoxicillin + PPI |
| High clarithromycin resistance area | BQT or vonoprazan-based regimen |
| Multiple prior failures | Susceptibility-guided therapy (culture or molecular testing); rifabutin-based regimen |
| Pregnancy | Defer treatment if possible; if needed, amoxicillin + metronidazole + PPI (avoid clarithromycin, tetracycline, bismuth in 1st trimester) |
Key Rules to Maximize Success
- 14 days is superior to 7 or 10 days for most regimens
- Take with food to reduce side effects (and for BQT, take bismuth and antibiotics with meals)
- Do not miss doses - even 80% adherence significantly reduces eradication rates
- Stop smoking - smoking increases treatment failure (shown in multiple studies)
- Confirm eradication with stool antigen test or urea breath test ≥4 weeks after completing therapy
- If first-line fails, always try a different antibiotic combination - do not repeat the same regimen
- Harrison's Principles of Internal Medicine 22E (2025), p. 1345-1346
- Goldman-Cecil Medicine, p. 4236-4238
- Yamada's Textbook of Gastroenterology, 7th ed.
- ACG Clinical Guideline: Treatment of H. pylori Infection, 2024
- Therapeutic advances in H. pylori eradication, PMC 2025
This is a shared conversation. Sign in to Orris to start your own chat.